Abstract
The p85α subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85α null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85α null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCγ (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85α, Btk, BLNK and PLCγ) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (G0) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca2+ entry (SK&F 96365) or PKC (Gö6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca2+ and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arcaro A and Wymann MP . (1993). Biochem. J., 296, 297–301.
Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T and Tsukada S . (2001). Proc. Natl. Acad. Sci. USA, 98, 2582–2586.
Banerji L, Glassford J, Lea NC, Thomas NS, Klaus GG and Lam EW-F . (2001). Oncogene, 20, 7352–7367.
Brorson K, Brunswick M, Ezhevsky S, Wei DG, Berg R, Scott D and Stein KE . (1997). J. Immunol., 159, 135–143.
Cantley LC . (2002). Science, 296, 1655–1657.
Cariappa A and Pillai S . (2002). Curr. Opin. Immunol., 14, 241–249.
Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, Vigorito E and Turner M . (2002). J. Exp. Med., 196, 753–763.
DeFranco AL . (2001). Nat. Immunol., 2, 482–484.
Dijkers PF, Birkenkamp KU, Lam EW-F, Thomas NS, Lammers JW, Koenderman L and Coffer PJ . (2002). J. Cell Biol., 156, 531–542.
Downward J . (1999). Nat. Cell Biol., 1, E33–E35.
Dyson N . (1998). Genes Dev., 12, 2245–2262.
Fasolato C, Pizzo P and Pozzan T . (1990). J. Biol. Chem., 265, 20351–20355.
Fruman DA, Satterthwaite AB and Witte ON . (2000). Immunity, 13, 1–3.
Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW and Cantley LC . (1999). Science, 283, 393–397.
Fu C and Chan AC . (1997). J. Biol. Chem., 272, 27362–27368.
Fu C, Turck CW, Kurosaki T and Chan AC . (1998). Immunity, 9, 93–103.
Glassford J, Holman M, Banerji L, Clayton E, Klaus GG, Turner M and Lam EW-F . (2001). J. Biol. Chem., 276, 41040–41048.
Grana X, Garriga J and Mayol X . (1998). Oncogene, 17, 3365–3383.
Gulbranson-Judge A, Tybulewicz VL, Walters AE, Toellner KM, MacLennan IC and Turner M . (1999). Eur. J. Immunol., 29, 477–487.
Hahner L, McQuilkin S and Harris RA . (1991). FASEB J., 5, 2466–2472.
Hayashi K, Nittono R, Okamoto N, Tsuji S, Hara Y, Goitsuka R and Kitamura D . (2000). Proc. Natl. Acad. Sci. USA, 97, 2755–2760.
Johnson-Leger C, Christenson JR, Holman M and Klaus GG . (1998). J. Immunol., 161, 4618–4126.
Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, Davidson L, Muller S, Kantor AB and Herzenberg LA . (1995). Immunity, 3, 283–299.
King LB, Norvell A and Monroe JG . (1999). J. Immunol., 162, 2655–2662.
Klaus GG, Holman M, Johnson-Leger C, Elgueta-Karstegl C and Atkins C . (1997). Eur. J. Immunol., 27, 2749–2756.
Klaus GG, O'Garra A, Bijsterbosch MK and Holman M . (1986). Eur. J. Immunol., 16, 92–97.
Kurosaki T . (1999). Annu. Rev. Immunol., 17, 555–592.
Kurosaki T . (2000). Curr. Opin. Immunol., 12, 276–281.
Kurosaki T, Maeda A, Ishiai M, Hashimoto A, Inabe K and Takata M . (2000). Immunol. Rev., 176, 19–29.
Lam EW, Choi MS, van der Sman J, Burbidge SA and Klaus GG . (1998). J. Biol. Chem., 213, 10051–10057.
Lam EW-F, Glassford J, Banerji L, Thomas NS, Sicinski P and Klaus GG . (2000). J. Biol. Chem., 275, 3479–3484.
Lam EW-F, Glassford J, van der Sman J, Banerji L, Pizzey AR, Thomas NSB and Klaus GGB . (1999). Eur. J. Immunol., 29, 3380–3389.
Lam EW-F and La Thangue NB . (1994). Curr. Opin. Cell Biol., 6, 859–866.
Lam KP, Kuhn R and Rajewsky K . (1997). Cell, 90, 1073–1083.
Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, Slingerland JM and Amati B . (1998). Oncogene, 17, 2637–2643.
Leevers SJ, Vanhaesebroeck B and Water-field MD . (1999). Curr. Opin. Cell Biol., 11, 219–225.
Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S and Tarakhovsky A . (1996). Science, 273, 788–791.
Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M and Uckun FM . (1999). J. Biol. Chem., 274, 9587–9599.
Mahajan S, Vassilev A, Sun N, Ozer Z, Mao C and Uckun FM . (2001). J. Biol. Chem., 276, 31216–31228.
Martino A, Holmes JHt, Lord JD, Moon JJ and Nelson BH . (2001). J. Immunol., 166, 1723–1729.
Merritt JE, Armstrong WP, Benham CD, Hallam TJ, Jacob R, Jaxa-Chamiec A, Leigh BK, McCarthy SA, Moores KE and Rink TJ . (1990). Biochem. J., 271, 515–522.
Muthukkumar S, Udhayakumar V and Bondada S . (1993). Eur. J. Immunol., 23, 2419–2426.
Nishizuka Y . (1992). Science, 258, 607–614.
O'Rourke LM, Tooze R, Turner M, Sandoval DM, Carter RH, Tybulewicz VL and Fearon DT . (1998). Immunity, 8, 635–645.
Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ and Vanhaesebroeck B . (2002). Science, 297, 1031–1034.
Petro JB, Castro I, Lowe J and Khan WN . (2002). FEBS Lett., 532, 57–60.
Qiu Y and Kung HJ . (2000). Oncogene, 19, 5651–5661.
Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, Fluckiger AC, Witte OK and Kinet JP . (1996). Science, 271, 822–825.
Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C and Tarakhovsky A . (2002). J. Exp. Med., 195, 1647–1652.
Sardet C, LeCam LE, Fabbrizio E and Vidal M . (1997). Oncogenes as Transcriptional Regulators, Vol. 2: Oncogenes as Transcriptional Regulators. Ghysdael J and Yaniv M (eds). Birkhauser Verlag: Berlin, Germany, pp. 1–63.
Satterthwaite AB, Li Z and Witte ON . (1998). Semin. Immunol., 10, 309–316.
Scharenberg AM and Kinet JP . (1998). Cell, 94, 5–8.
Scheid MP and Duronio V . (1998). Proc. Natl. Acad. Sci. USA, 95, 7439–7444.
Sherr CJ . (2000). Cancer Res., 60, 3689–3695.
Sherr CJ and Roberts JM . (1999). Genes Dev., 13, 1501–1512.
Solvason N, Wu WW, Kabra N, Lund-Johansen F, Roncarolo MG, Behrens TW, Grillot DA, Nunez G, Lees E and Howard M . (1998). J. Exp. Med., 187, 1081–1891.
Solvason N, Wu WW, Parry D, Mahony D, Lam EW, Glassford J, Klaus GG, Sicinski P, Weinberg R, Liu YJ, Howard M and Lees E . (2000). Int. Immunol., 12, 631–638.
Suzuki H, Terauchi Y, Fujiwara M, Aizawa S, Yazaki Y, Kadowaki T and Koyasu S . (1999). Science, 283, 390–392.
Tan JE, Wong SC, Gan SK, Xu S and Lam KP . (2001). J. Biol. Chem., 276, 20055–20063.
Tarakhovsky A, Turner M, Schaal S, Mee PJ, Duddy LP, Rajewsky K and Tybulewicz VL . (1995). Nature, 374, 467–470.
Thompson AK, Mostafapour SP, Denlinger LC, Bleasdale JE and Fisher SK . (1991). J. Biol. Chem., 266, 23856–23862.
Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E and Loriolle F . (1991). J. Biol. Chem., 266, 15771–15781.
Tsukada S, Baba Y and Watanabe D . (2001). Adv. Immunol., 77, 123–162.
Tsukada S, Rawlings DJ and Witte ON . (1994). Curr. Opin. Immunol., 6, 623–630.
Vihinen M, Belohradsky BH, Haire RN, Holinski-Feder E, Kwan SP, Lappalainen I, Lehvaslaiho H, Lester T, Meindl A, Ochs HD, Ollila J, Vorechovsky I, Weiss M and Smith CI . (1997). Nucleic Acids Res., 25, 166–171.
Vihinen M, Cooper MD, de Saint Basile G, Fischer A, Good RA, Hendriks RW, Kinnon C, Kwan SP, Litman GW, Notarangelo LD et al. (1995). Immunol. Today, 16, 460–465.
Vlahos CJ, Matter WF, Hui KY and Brown RF . (1994). J. Biol. Chem., 269, 5241–5248.
Wang D, Feng J, Wen R, Marine JC, Sangster MY, Parganas E, Hoffmeyer A, Jackson CW, Cleveland JL, Murray PJ and Ihle JN . (2000). Immunity, 13, 25–35.
Williams CD, Linch DC, Watts MJ and Thomas NS . (1997). Blood, 90, 194–203.
Xu S, Tan JE, Wong EP, Manickam A, Ponniah S and Lam KP . (2000). Int. Immunol., 12, 397–404.
Zhang R, Alt FW, Davidson L, Orkin SH and Swat W . (1995). Nature, 374, 470–473.
Acknowledgements
J Glassford and EW-F Lam are also supported by the Leukaemia Research Fund. I Soeiro is supported by a PhD studentship from Fundação para a Ciência e a Tecnologia, Portugal. L Banerji was supported by a University of London Trust Postgraduate Studentship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Glassford, J., Soeiro, I., Skarell, S. et al. BCR targets cyclin D2 via Btk and the p85α subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene 22, 2248–2259 (2003). https://doi.org/10.1038/sj.onc.1206425
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206425
Keywords
This article is cited by
-
Role of Bruton’s tyrosine kinase in B cells and malignancies
Molecular Cancer (2018)
-
Mediation of transitional B cell maturation in the absence of functional Bruton’s tyrosine kinase
Scientific Reports (2017)
-
U-73122 reduces the cell growth in cultured MG-63 ostesarcoma cell line involving Phosphoinositide-specific Phospholipases C
SpringerPlus (2016)
-
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
Current Hematologic Malignancy Reports (2016)
-
Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations
Blood Cancer Journal (2012)